1. Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue
- Author
-
Tian-Qi Mao, Erik De Clercq, Zheng-Yong Wan, Jin Yao, Dirk Daelemans, Fen-Er Chen, Xinlong Wang, Christophe Pannecouque, Hong Yin, Wen-Xue Chen, and Haifeng Wang
- Subjects
Models, Molecular ,Pyrimidine ,Anti-HIV Agents ,Allosteric regulation ,Mutant ,medicine.disease_cause ,Conserved sequence ,chemistry.chemical_compound ,Drug Discovery ,Tumor Cells, Cultured ,medicine ,Humans ,Potency ,Conserved Sequence ,Pharmacology ,Mutation ,Molecular Structure ,Chemistry ,Organic Chemistry ,Biological activity ,General Medicine ,Molecular biology ,HIV Reverse Transcriptase ,Reverse transcriptase ,Pyrimidines ,Biochemistry ,HIV-1 ,Reverse Transcriptase Inhibitors ,Acetanilides - Abstract
Based on molecular simulation, the etravirine-VRX-480773 hybrids previously disclosed by our group were optimized to yield novel pyrimidine sulfonylacetanilides 8 with improved activity against a panel of seven clinically relevant single and double mutant strains of HIV-1. The improvement in potency in this in vitro model of HIV RNA replication partly validates the mechanism by which this class of allosteric pyrimidine derivatives inhibits the reverse transcriptase (RT), and represents a remarkable step forward in the development of anti-HIV drugs.
- Published
- 2015
- Full Text
- View/download PDF